Actively Recruiting
Evaluating the Effects of Dapagliflozin on Coronary Inflammation Using Photon-counting CT in Stage 4 CKM Syndrome Patients
Led by Shenyang Northern Hospital · Updated on 2026-10-30
110
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying whether dapagliflozin, a sodium-glucose cotransporter 2 inhibitor SGLT2i, can reduce coronary inflammation in patients with stage 4 CKM syndrome, a condition involving high cardiovascular risk and chronic inflammation. This study aims to measure coronary inflammation using the fat attenuation index FAI derived from coronary CT angiography CCTA and assess if dapagliflozin can also slow the progression of coronary plaques. Participants will be randomly assigned to either receive dapagliflozin 10 mg daily along with standard therapy or standard therapy alone for 6 months. All participants will have undergone percutaneous coronary intervention PCI for acute coronary syndrome ACS and will have a baseline CCTA scan one month after PCI. Follow-up CCTA scans will be done 6 months after randomization to evaluate changes. During the study, participants will receive follow-up phone calls at 3 and 6 months after randomization to monitor progress. Researchers will assess changes in FAI from baseline to 6 months and measure changes in various types of coronary plaque volumes and stenosis. The study includes safety and clinical outcome monitoring throughout the 6-month treatment period.
CONDITIONS
Brief Title
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here